187 related articles for article (PubMed ID: 32146594)
1. Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.
Ming J; Liu WY; Xiao HY; Xu YG; Ma R; Hu XM
Chin J Integr Med; 2022 Aug; 28(8):762-768. PubMed ID: 32146594
[TBL] [Abstract][Full Text] [Related]
2. Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder () in Patients with Myelodysplastic Syndrome.
Deng ZY; Zhu SR; Wang MJ; Fang S; Zhao P; Zhu QZ; Wang HZ; Guo XQ; Xu YG; Yi BW; Shang XH; Ma R; Hu XM
Chin J Integr Med; 2019 Jul; 25(7):497-501. PubMed ID: 31278627
[TBL] [Abstract][Full Text] [Related]
3. Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.
Zhao P; Liang JB; Deng ZY; Wang MJ; Qin JY; Chen CJ; Hu XM
Chin J Integr Med; 2019 Jun; 25(6):409-415. PubMed ID: 29619748
[TBL] [Abstract][Full Text] [Related]
4. Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia.
Wu YH; Xiao HY; Quan RC; Tang XD; Liu WY; Lyu Y; Chen Z; Liu C; Hu XM
Chin J Integr Med; 2023 Sep; 29(9):832-837. PubMed ID: 37222831
[TBL] [Abstract][Full Text] [Related]
5. Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.
Fan T; Quan RC; Liu WY; Xiao HY; Tang XD; Liu C; Li L; Lv Y; Wang HZ; Xu YG; Guo XQ; Hu XM
Chin J Integr Med; 2020 May; 26(5):339-344. PubMed ID: 31848890
[TBL] [Abstract][Full Text] [Related]
6. Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation.
Zhou QB; Yang XH; Wang HZ; Wang DX; Xu YG; Hu XM; Xu FQ; Ma R
Chin J Integr Med; 2019 May; 25(5):354-359. PubMed ID: 29500545
[TBL] [Abstract][Full Text] [Related]
7. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7.
Hu XM; Tanaka S; Onda K; Yuan B; Toyoda H; Ma R; Liu F; Hirano T
Chin J Integr Med; 2014 May; 20(5):387-93. PubMed ID: 24610410
[TBL] [Abstract][Full Text] [Related]
8. Arsenic Dispensing Powder Promotes Erythropoiesis in Myelodysplastic Syndromes via Downregulation of HIF1A and Upregulation of GATA Factors.
Fan T; Feng X; Yokota A; Liu W; Tang Y; Yan X; Xiao H; Wang Y; Deng Z; Zhao P; Wang M; Wang H; Ma R; Hu X; Huang G
Am J Chin Med; 2021; 49(2):461-485. PubMed ID: 33641653
[TBL] [Abstract][Full Text] [Related]
9. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder.
Xu S; Ma R; Hu XM; Xu YG; Yang XH; Wang HZ; Sun SZ; Liu F
Chin J Integr Med; 2011 Nov; 17(11):834-9. PubMed ID: 22057412
[TBL] [Abstract][Full Text] [Related]
10. [Effect of Qinghuang Powder combined Chinese herbs for Pi-strengthening and Shen-reinforcing on HIF-1alpha in bone marrow mononuclear cells of myelodysplastic syndrome patients: an experimental research].
Gao F; Xu YG; Yang XH; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):174-8. PubMed ID: 24672941
[TBL] [Abstract][Full Text] [Related]
11. Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome.
Zhu Q; Deng Z; Zhu S; Zhao P; Wang M; Hu X
Evid Based Complement Alternat Med; 2017; 2017():2095682. PubMed ID: 29348764
[TBL] [Abstract][Full Text] [Related]
12. [Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing shen and strenghening pi].
Xu S; Hu XM; Xu YG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Mar; 28(3):216-8. PubMed ID: 18476419
[TBL] [Abstract][Full Text] [Related]
13. Arsenic concentration in peripheral blood is correlated with efficacy of a Traditional Chinese Medicine regimen containing realgar for the treatment of myelodysplastic syndrome.
Wang DX; Xu YG; Du Y; Wang HZ; Li L; Hu XM; Yang XP; Ma R; Zhou QB
J Tradit Chin Med; 2021 Aug; 41(4):630-635. PubMed ID: 34392657
[TBL] [Abstract][Full Text] [Related]
14. Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome.
Zhou QB; Liu ZT; Wang HZ; Guo XQ; Xu YG; Hu XM
Drug Des Devel Ther; 2020; 14():1641-1650. PubMed ID: 32431489
[TBL] [Abstract][Full Text] [Related]
15. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.
Hu XM; Liu F; Ma R
Chin J Integr Med; 2010 Aug; 16(4):368-77. PubMed ID: 20697951
[TBL] [Abstract][Full Text] [Related]
16. [Effect of treatment for hypocellular myelodysplastic syndromes by a low dose qinghuang powder combined with Chinese drugs for Shen supplementing and Pi invigorating: a clinical observation].
Zhou QB; Wang HZ; Gao F; Tang XD; Xu S; Yang XH; Xu YG; Hu XM; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Dec; 34(12):1444-8. PubMed ID: 25632743
[TBL] [Abstract][Full Text] [Related]
17. [Effects of qinghuang power combined Chinese herbs for shen reinforcing and Pi strengthening on activated T cells of myelodysplastic syndrome patients].
Gao F; Ma R; Yang XH; Xu YG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Apr; 33(4):443-7. PubMed ID: 23841258
[TBL] [Abstract][Full Text] [Related]
18. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
[TBL] [Abstract][Full Text] [Related]
19. Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro.
Xu M; Ren JY; Guo YC; Xu BX; Zeng Q; Hu Q; Zhou YM; Lu JH
Leuk Res; 2017 Nov; 62():4-11. PubMed ID: 28963909
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
